Search Results - "VERONESE, Maria Luisa"

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors by DEMETRI, George D, CASALI, Paolo G, PINK, Daniel, DEBIEC-RYCHTER, Maria, WING CHEUNG, BAILEY, Stuart M, LUISA VERONESE, Maria, REICHARDT, Annette, FUMAGALLI, Elena, REICHARDT, Peter, BLAY, Jean-Yves, VON MEHREN, Margaret, MORGAN, Jeffrey A, BERTULLI, Rossella, RAY-COQUARD, Isabelle, CASSIER, Philippe, DAVEY, Monica, BORGHAEI, Hossein

“…Purpose: To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with…”
Get full text

Mechanisms of Hypertension Associated With BAY 43-9006 by VERONESE, Maria Luisa, MOSENKIS, Ari, FLAHERTY, Keith T, GALLAGHER, Maryann, STEVENSON, James P, TOWNSEND, Raymond R, O'DWYER, Peter J

“…BAY 43-9006 (sorafenib) is an inhibitor of Raf kinase, the vascular endothelial growth factor (VEGF) receptor-2, and angiogenesis in tumor xenografts. The…”
Get full text

Identification of a Gene at 11q23 Encoding a Guanine Nucleotide Exchange Factor: Evidence for Its Fusion with MLL in Acute Myeloid Leukemia by Kourlas, Peter J., Strout, Matthew P., Becknell, Brian, Veronese, Maria Luisa, Croce, Carlo M., Theil, Karl S., Krahe, Ralf, Ruutu, Tapani, Knuutila, Sakari, Bloomfield, Clara D., Caligiuri, Michael A.

“…We have identified a gene at 11q23, telomeric to MLL, that encodes a guanine nucleotide exchange factor (GEF). This gene is transcribed into a 9.5-kb mRNA…”
Get full text

The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer by Sozzi, Gabriella, Veronese, Maria Luisa, Negrini, Massimo, Baffa, Raffaele, Cotticelli, Maria Grazia, Inoue, Hiroshi, Tornielli, Silvana, Pilotti, Silvana, De Gregorio, Laura, Pastorino, Ugo, Pierotti, Marco A, Ohta, Masataka, Huebner, Kay, Croce, Carlo M

“…To determine the role of the FHIT gene, which encompasses the fragile site at 3p14.2, we analyzed 59 tumors of the small cell and non-small cell type by…”
Get full text

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations by Hyman, David M, Puzanov, Igor, Subbiah, Vivek, Faris, Jason E, Chau, Ian, Blay, Jean-Yves, Wolf, Jürgen, Raje, Noopur S, Diamond, Eli L, Hollebecque, Antoine, Gervais, Radj, Elez-Fernandez, Maria Elena, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep, Baselga, José

“…In a basket trial that included patients with a variety of cancers, all of which contained a BRAF V600 mutation, the rate of response to vemurafenib was highly…”
Get full text

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial by Rodón, Jordi, Damian, Silvia, Furqan, Muhammad, García-Donas, Jesús, Imai, Hiroo, Italiano, Antoine, Spanggaard, Iben, Ueno, Makoto, Yokota, Tomoya, Veronese, Maria Luisa, Oliveira, Natalia, Li, Xin, Gilmartin, Aidan, Schaffer, Michael, Goyal, Lipika

“…Fibroblast growth factor receptor ( FGFR ) alterations drive oncogenesis in multiple tumor types. Here we studied pemigatinib, a selective, potent, oral…”
Get full text

Publisher Correction: Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial by Rodón, Jordi, Damian, Silvia, Furqan, Muhammad, García-Donas, Jesús, Imai, Hiroo, Italiano, Antoine, Spanggaard, Iben, Ueno, Makoto, Yokota, Tomoya, Veronese, Maria Luisa, Oliveira, Natalia, Li, Xin, Gilmartin, Aidan, Schaffer, Michael, Goyal, Lipika

Get full text

Modified study designs to expand treatment options in personalised oncology: a multistakeholder view by Le Tourneau, Christophe, André, Fabrice, Helland, Åslaug, Mileshkin, Linda, Minnaard, Warnyta, Schiel, Anja, Taskén, Kjetil, Thomas, David M., Veronese, Maria Luisa, Durán-Pacheco, Gonzalo, Leyens, Lada, Rufibach, Kaspar, Thomas, Marlene, Krämer, Alwin

“…Personalised oncology, whereby patients are given therapies based on their molecular tumour profile, is rapidly becoming an essential part of optimal clinical…”
Get full text

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement by Vannucchi, Alessandro M., Patel, Jay L., Shomali, William E., George, Tracy I., Reiter, Andreas, Rambaldi, Alessandro, Oh, Stephen, Usuki, Kensuke, Harrison, Claire N., Luisa Veronese, Maria, Gilmartin, Aidan, Zhen, Huiling, Verstovsek, Srdan, Oliveira, Natalia, Gotlib, Jason, Kiladjian, Jean-Jacques

Get full text

MPN-384 A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement by Vannucchi, Alessandro M., Patel, Jay L., Shomali, William E., George, Tracy I., Reiter, Andreas, Rambaldi, Alessandro, Oh, Stephen, Usuki, Kensuke, Harrison, Claire N., Luisa Veronese, Maria, Gilmartin, Aidan, Zhen, Huiling, Verstovsek, Srdan, Oliveira, Natalia, Gotlib, Jason, Kiladjian, Jean-Jacques

“…Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLNFGFR1) are rare hematologic malignancies caused by 8p11 translocations, resulting in FGFR1 fusions and…”
Get full text

A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement by Vannucchi, Alessandro M., Patel, Jay L., Shomali, William E., George, Tracy I., Reiter, Andreas, Rambaldi, Alessandro, Oh, Stephen, Usuki, Kensuke, Harrison, Claire N., Luisa Veronese, Maria, Gilmartin, Aidan, Zhen, Huiling, Verstovsek, Srdan, Oliveira, Natalia, Gotlib, Jason, Kiladjian, Jean-Jacques

Get full text

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC) by Tabernero, Josep, Chan, Emily, Baselga, Jose, Blay, Jean-Yves, Chau, Ian, Hyman, David Michael, Raje, Noopur S., Wolf, Juergen, Sirzen, Florin, Veronese, Maria Luisa, Mitchell, Lada, Hidalgo, Manuel

“…Abstract only…”
Get full text

VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m) by Hyman, David Michael, Blay, Jean-Yves, Chau, Ian, Raje, Noopur S., Fernandez, Maria Elena Elez, Wolf, Juergen, Sirzen, Florin, Veronese, Maria Luisa, Mitchell, Lada, Puzanov, Igor, Baselga, Jose

“…Abstract only…”
Get full text

Monoclonal antibodies in the treatment of colorectal cancer by Veronese, Maria Luisa, O'Dwyer, Peter J.

“…Monoclonal antibodies have been developed to target specific proteins involved in the development and progression of cancer. These reagents have the advantage…”
Get full text

The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study by Hyman, David M., Diamond, Eli, Subbiah, Vivek, Blay, Jean-Yves, Lockhart, A. Craig, Abdel-Wahab, Omar, Sirzen, Florin, Veronese, Maria Luisa, Laserre, Susan Frances, Elez, Elena, Baselga, Jose

“…Background: The systemic histiocytic disorders Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are rare hematologic malignancies with…”
Get full text

Open-label, multicenter safety study of vemurafenib in patients with BRAF V600 mutation–positive metastatic melanoma by Larkin, James M. G., Del Vecchio, Michele, Ascierto, Paolo Antonio, Schachter, Jacob, Garbe, Claus, Neyns, Bart, Mandala, Mario, Lorigan, Paul, Miller, Wilson H, Guminski, Alexander David, Berking, Carola, Rutkowski, Piotr, Queirolo, Paola, Hauschild, Axel, Arance, Ana Maria, Brown, Michael Paul, Mitchell, Lada, Veronese, Maria Luisa, Blank, Christian U.

“…Abstract only 9046 Background: Vemurafenib (VEM), a BRAF kinase inhibitor, has demonstrated high response rates and improved progression-free and overall…”
Get full text

FHIT Gene Alterations in Head and Neck Squamous Cell Carcinomas by Virgilio, Laura, Shuster, Michele, Gollin, Susanne M., Veronese, Maria Luisa, Ohta, Masataka, Huebner, Kay, Croce, Carlo M.

“…To determine whether the FHIT gene at 3p14.2 is altered in head and neck squamous cell carcinomas (HNSCC), we examined 26 HNSCC cell lines for deletions within…”
Get full text

An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma by Larkin, James M. G., Queirolo, Paola, Arance, Ana M, Brown, Michael Paul, Hauschild, Axel, Del Vecchio, Michele, McArthur, Grant A., Neyns, Bart, Becker, Jürgen C., Hansson, Johan, Hogg, David, Ascierto, Paolo Antonio, Loquai, Carmen, Espinosa, Enrique, Garbe, Claus, Patel, Poulam M, Schachter, Jacob, Mitchell, Lada, Veronese, Maria Luisa, Blank, Christian U.

“…Abstract only 8517 Background: Vemurafenib, a BRAF inhibitor, is associated with improved PFS and OS in patients (pts) with BRAF V600 -mutant metastatic…”
Get full text

Structure and expression of the human FHIT gene in normal and tumor cells by DRUCK, T, HADACZEK, P, ROTHSTEIN, J, MCCUE, P, COTTICELLI, M. G, INOUE, H, CROCE, C. M, HUEBNER, K, FU, T.-B, OHTA, M, SIPRASHVILI, Z, BAFFA, R, NEGRINI, M, KASTURY, K, VERONESE, M. L, ROSEN, D

“…The FHIT gene, encoded by 10 exons in a 1.1-kb transcript, encompasses approximately 1 Mb of genomic DNA, which includes the hereditary RCC t(3;8)…”
Get full text

Loss of FHIT expression in gastric carcinoma by BAFFA, R, VERONESE, M. L, SANTORO, R, MANDES, B, PALAZZO, J. P, RUGGE, M, SANTORO, E, CROCE, C. M, HUEBNER, K

“…Loss of heterozygosity involving the short arm of chromosome 3 has been reported in gastric and other human tumors. We have cloned and mapped a candidate tumor…”
Get full text